GSR Ventures

Health Tech

ROI and Clinical Validation Will Determine Digital Health Startups’ Success in 2023, Investors Say

Going into 2023, investors think the abilities to demonstrate ROI and clinical validation will be the most important factors determining digital health companies' success, according to a new report. While the ROI factor is a given, clinical validation “is the best signal of patient value and historically has been under-captured in digital health," said Sunny Kumar, a partner at GSR Ventures.

Health Tech

Why Digital Health Funding Fell 36% in Q3

During Q3, digital health's funding fell 36% quarter-over-quarter and 72% from its all-time high during last year’s Q2. The primary driver of this reduction is macro market trends, experts said, though digital health companies need to tie their services more directly to value to get funding in the future.

sponsored content

A Deep-dive Into Specialty Pharma

A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.